Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Quality of Life and Global Response Score in Cutaneous T-Cell Lymphoma

Niloufer Khan, Esther Drill, Alison Moskowitz, Michi M Shinohara, Cecilia Larocca, Christiane Querfeld, Jasmine M. Zain, Steven M. Horwitz

Blood (2023) 142 (Supplement 1): 381.

https://doi.org/10.1182/blood-2023-173713

Published: 2023

Journal Articles

The Influence of TET2 and/or DNMT3A Knockout on the 5hmC Levels and Growth Characteristics of Modified Human Primary CD4 T Cells after Activation

Ruimeng Yang, Xuxiang Liu, Jibin Zhang, Yuping Li, Krystie Chew, Claire Wu, Jasmine M. Zain, Joo Y. Song, Waseem Gul Lone, Javeed Iqbal, Wing C. Chan

Blood (2023) 142 (Supplement 1): 2775.

https://doi.org/10.1182/blood-2023-187176

Published: 2023

Journal Articles

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine M. Zain

Blood (2023) 142 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2023-188053

Published: 2023

Journal Articles

A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma

Blood (2023) 142 (7): 621–628.

https://doi.org/10.1182/blood.2023020244

Published: 2023

Journal Articles

A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-136465

Published: 2020

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results

Barbara Pro, MD, Jonathan E. Brammer, MD, Carla Casulo, MD, Eric Jacobsen, MD, Monica Mead, MD BS, Neha Mehta-Shah, MD, Jasmine M. Zain, MD, Pier Luigi Zinzani, MD, Stephanie Lustgarten, PhD, Hagop Youssoufian, MD, Steven M. Horwitz, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-140412

Published: 2020

Journal Articles

Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-137258

Published: 2020

Journal Articles

Tnfα Promotes an Immunosuppressive Microenvironment in Cutaneous T Cell Lymphoma and Regulates PD-L1 Expression

Emine Gulsen Gunes, PhD, Sung Hee Kil, PhD, Xiwei Wu, PhD, Chingyu Su, Zhen Han, Hanjun Qin, PhD, Ting-Fang He, PhD, Jing Chen, Yukiko Yamaguchi, PhD, Jasmine M. Zain, MD, Farah Abdulla, MD, Saul Priceman, PhD, Mingye Feng, PhD, Peter P. Lee, MD, Steven T. Rosen, MD, Christiane Querfeld, MDPhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-141070

Published: 2020

Journal Articles

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Christiane Querfeld, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Paul Frohna, MD PhD PharmD, Nazli Azimi, PhD PharmD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 1557.

https://doi.org/10.1182/blood-2019-129201

Published: 2019

Journal Articles

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, NI-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 4623.

https://doi.org/10.1182/blood-2019-131357

Published: 2019

Journal Articles

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, Ni-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Ibrahim Aldoss, MD, Vinod A. Pullarkat, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 5729.

https://doi.org/10.1182/blood-2019-131437

Published: 2019

Journal Articles

Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation

Alex Iukuridze, Meisi Xiao, MPH, Lee Brandyn, Jennifer Berano Teh, Kristen Mascarenhas, Sandra Xu, Nicholas Rosen, Jeannine S McCune, PharmD, Jasmine M. Zain, MD, Robert W. Chen, MD, Leslie Popplewell, MD, Jessica Scott, PhD, Thomas Slavin, MD, Lee Jones, PhD, Stephen J Forman, Ryotaro Nakamura, MD, F. Lennie Wong, PhD, Saro H. Armenian, DO,MPH

Blood (2018) 132 (Supplement 1): 620.

https://doi.org/10.1182/blood-2018-99-113689

Published: 2018

Journal Articles

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Blood (2018) 132 (Supplement 1): 228.

https://doi.org/10.1182/blood-2018-99-110220

Published: 2018

Journal Articles

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Swami P. Iyer, MD, Auris Huen, MD, Andres J M Ferreri, MD, Bradley M. Haverkos, MD MPH, MS, Jasmine M. Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Richard Delarue, MD, Kasi V Routhu, PhD, Prajak Barde, MD, Ajit M Nair, PhD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2018-99-112757

Published: 2018

Journal Articles

Phase 1/2 Trial of Durvalumab and Lenalidomide in Patients with Cutaneous T Cell Lymphoma (CTCL): Preliminary Results of Phase I Results and Correlative Studies

Christiane Querfeld, MD PhD, Jasmine M. Zain, MD, Devin L. Wakefield, PhD, Tijana Jovanovic-Talisman, PhD, Sung Hee Kil, PhD, Renee Estephan, BS, James Sanchez, PhD, Joycelynne Palmer, Steven T Rosen

Blood (2018) 132 (Supplement 1): 2931.

https://doi.org/10.1182/blood-2018-99-114001

Published: 2018

Journal Articles

Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results

Matthew A. Lunning, DO, Steven M. Horwitz, MD, Ranjana Advani, MD, Julie M. Vose, MDMBA, Hun Ju Lee, MD, Neha Mehta-Shah, MD, Jasmine M. Zain, MD, Bradley M. Haverkos, MD MPH, MS, Mary Jo Lechowicz, MD, Alison J. Moskowitz, MD, Luu Q. Pham, Elizabeth R. Lyden, MS, Peggy Heires, R.N., Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 2899.

https://doi.org/10.1182/blood-2018-99-114110

Published: 2018

Journal Articles

Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) — Results from a Prospective Multicenter Phase 2 Clinical Trial

Andrei R Shustov, MD, Michi M Shinohara, MD, Shaker R. Dakhil, MD, Gajanan Bhat, Jasmine M. Zain, MD

Blood (2018) 132 (Supplement 1): 2910.

https://doi.org/10.1182/blood-2018-99-119684

Published: 2018

Journal Articles

Mutations in the Phosphoinositide 3-Kinase Pathway (PI3K) Are Associated with Poor Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Blood (2017) 130 (Supplement 1): 2740.

https://doi.org/10.1182/blood.V130.Suppl_1.2740.2740

Published: 2017

Journal Articles

Ruxolinitib As Salvage Therapy for Chronic Graft-Versus-Host Disease

Badri Modi, MD, Michael Hernandez-Henderson, B.A., Erin Kopp, Dongyun Yang, PhD, Karen Huelsman, R.N., Pietro Sollena, MD, Jasmine M. Zain, MD, Haris Ali, MD, Monzr M. Al Malki, MD, Ricardo Spielberger, MD, Sanjeet Dadwal, MD, Amandeep Salhotra, MD, Stephen J. Forman, MD FACP, Pablo Parker, MD, Ryotaro Nakamura, MD

Blood (2017) 130 (Supplement 1): 1976.

https://doi.org/10.1182/blood.V130.Suppl_1.1976.1976

Published: 2017

Journal Articles

PD-L1 Is Regulated By Interferon Gamma and Interleukin 6 through STAT1 and STAT3 Signaling in Cutaneous T-Cell Lymphoma

Sung Hee Kil, PhD, Renee Estephan, BS, James Sanchez, PhD, Jasmine M. Zain, MD, Marshall E. Kadin, MD, James W. Young, MD, Steven T. Rosen, MD, Christiane Querfeld, MD PhD

Blood (2017) 130 (Supplement 1): 1458.

https://doi.org/10.1182/blood.V130.Suppl_1.1458.1458

Published: 2017

NARROW

Quality of Life and Global Response Score in Cutaneous T-Cell Lymphoma

The Influence of TET2 and/or DNMT3A Knockout on the 5hmC Levels and Growth Characteristics of Modified Human Primary CD4 T Cells after Activation

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma

A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results

Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Tnfα Promotes an Immunosuppressive Microenvironment in Cutaneous T Cell Lymphoma and Regulates PD-L1 Expression

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Phase 1/2 Trial of Durvalumab and Lenalidomide in Patients with Cutaneous T Cell Lymphoma (CTCL): Preliminary Results of Phase I Results and Correlative Studies

Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results

Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) — Results from a Prospective Multicenter Phase 2 Clinical Trial

Mutations in the Phosphoinositide 3-Kinase Pathway (PI3K) Are Associated with Poor Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Ruxolinitib As Salvage Therapy for Chronic Graft-Versus-Host Disease

PD-L1 Is Regulated By Interferon Gamma and Interleukin 6 through STAT1 and STAT3 Signaling in Cutaneous T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only